Latham & Watkins Represents Triumvira Immunologics in Completing Extension of Series A Financing

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, has announced the completion of an extension of its Series A financing, bringing the total round to approximately US$100 million. The Series A extension featured new investors, including significant participation from B Capital Group, along with ATEM Capital, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, and others, joined by significant participation from existing investors, Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures.

Latham & Watkins LLP represents Triumvira Immunologics in the financing with a corporate deal team led by New York partner Nathan Ajiashvili and Boston partner Dan Hoffman, with New York associates Sam Dillard and Saem Kim. Advice was also provided on benefits & compensation matters by Washington, D.C. partner David Della Rocca, with Washington, D.C. associate Marysia Mullen.